Athersys Signs $12 Million Registered Direct Offering
9:07AM ET 8/15/2022 MT NewswiresAthersys (ATHX) said Monday that a health care investor has agreed to purchase 48 million shares of the company's common stock at $0.25 per share in a...
Quotes Snapshot > ATHX
Athersys Inc ATHX:NASDAQ
Last Price$0.22Cboe Real-Time Last Sale as of 12:00PM ET 8/17/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.02(8.33%)
Bid (Size)$0.22 (100)
Ask (Size)$0.22 (3,900)
Day Low / High$0.22 - 0.24
Volume3.8 M
Read more news Recent News
Athersys Says Equity Purchase Deal With Aspire Capital Fund Has Been Terminated
7:59AM ET 7/08/2022 MT NewswiresAthersys (ATHX) said Friday that Aspire Capital Fund has terminated their equity purchase agreement on July 6. Athersys said it is currently evaluating...
Wall Street Set to Open Higher
9:16AM ET 6/17/2022 MT NewswiresUS stocks look set to open Friday trading higher as Federal Reserve Chairman Jerome Powell speaks before the inaugural Conference on the International...
View all Commentary and Analysis
Athersys, Inc. (ATHX) CEO Daniel Camardo on Q2 2022 Results - Earnings Call Transcript
11:07PM ET 8/11/2022 Seeking AlphaAthersys: Dead Man Walking
4:29PM ET 7/25/2022 Seeking AlphaAthersys (ATHX) Investor Presentation Treasure Data - Slideshow
1:31PM ET 5/26/2022 Seeking AlphaAthersys: Focus On Stroke
9:40AM ET 5/04/2022 Seeking AlphaCompany Profile
Business DescriptionAthersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH. View company web site for more details
| Address | 3201 Carnegie Avenue Cleveland, Ohio 44115-2634 |
| Phone | +1.216.431.9900 |
| Number of Employees | 75 |
| Recent SEC Filing | 08/17/2022 424B5 |
| CEO, Co-CFO, Secretary, Director & CAO | Daniel A. Camardo |
| Chief Operating Officer | Maia A. Hansen |
| Chief Financial Officer | Kasey Rosado |
| Head-Information Technology & Communications | Rakesh Ramachandran |
Company Highlights
| Price Open | $0.24 |
| Previous Close | $0.24 |
| 52 Week Range | $0.17 - 1.81 |
| Market Capitalization | $60.5 M |
| Shares Outstanding | 275.1 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/21/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.32 |
| Beta vs. S&P 500 | N/A |
| Revenue | $24.3 M |
| Net Profit Margin | -993.97% |
| Return on Equity | -434.69% |
Analyst Ratings as of 08/16/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |